These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31467662)

  • 1. Developments in chemotherapy for the treatment of acute myeloid leukemia.
    Drummond MW
    Int J Hematol Oncol; 2019 Jul; 8(2):IJH16. PubMed ID: 31467662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urological medical oncology: land of opportunity.
    Jones R
    Future Oncol; 2013 Feb; 9(2):149-52. PubMed ID: 23414465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
    Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
    Høilund-Carlsen PF
    Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy for melanoma.
    Ascierto PA; Larkin J
    Melanoma Manag; 2014 Aug; 1(1):19-24. PubMed ID: 30190806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib recommendations for ovarian cancer patients.
    Johnson P; Westcott G
    Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
    Kasner MT
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):604-606. PubMed ID: 31851160
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
    Murphy T; Yee KWL
    Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute myeloid leukemia of the elderly: recent progresses in therapy].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(6):735-740. PubMed ID: 29973453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Food and Drug Administration-Approved and Emerging Novel Treatment Options for Acute Myeloid Leukemia.
    Click ZR; Seddon AN; Bae YR; Fisher JD; Ogunniyi A
    Pharmacotherapy; 2018 Nov; 38(11):1143-1154. PubMed ID: 30220082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of early intervention in the treatment of hepatic veno-occlusive disease.
    Pagliuca A
    Int J Hematol Oncol; 2019 Jul; 8(2):IJH15. PubMed ID: 31467661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
    Chen EC; Fathi AT; Brunner AM
    Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco.
    Lo-Coco F
    Int J Hematol Oncol; 2016 Nov; 5(3):101-104. PubMed ID: 30302209
    [No Abstract]   [Full Text] [Related]  

  • 19. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
    Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
    J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
    Ravindranath Y
    Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.